176 related articles for article (PubMed ID: 27563009)
1. NEK7: a novel promising therapy target for NLRP3-related inflammatory diseases.
Xu J; Lu L; Li L
Acta Biochim Biophys Sin (Shanghai); 2016 Oct; 48(10):966-968. PubMed ID: 27563009
[No Abstract] [Full Text] [Related]
2. NEK7: a potential therapy target for NLRP3-related diseases.
Liu G; Chen X; Wang Q; Yuan L
Biosci Trends; 2020 May; 14(2):74-82. PubMed ID: 32295992
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in the NEK7-licensed NLRP3 inflammasome activation: Mechanisms, role in diseases and related inhibitors.
Zhao N; Li CC; Di B; Xu LL
J Autoimmun; 2020 Sep; 113():102515. PubMed ID: 32703754
[TBL] [Abstract][Full Text] [Related]
4. NEK7 mediated assembly and activation of NLRP3 inflammasome downstream of potassium efflux in ventilator-induced lung injury.
Liu H; Gu C; Liu M; Liu G; Wang Y
Biochem Pharmacol; 2020 Jul; 177():113998. PubMed ID: 32353421
[TBL] [Abstract][Full Text] [Related]
5. NIMA-related kinase 7 amplifies NLRP3 inflammasome pro-inflammatory signaling in microglia/macrophages and mice models of spinal cord injury.
Ji X; Song Z; He J; Guo S; Chen Y; Wang H; Zhang J; Xu X; Liu J
Exp Cell Res; 2021 Jan; 398(2):112418. PubMed ID: 33309808
[TBL] [Abstract][Full Text] [Related]
6. Glutathione Transferase Omega-1 Regulates NLRP3 Inflammasome Activation through NEK7 Deglutathionylation.
Hughes MM; Hooftman A; Angiari S; Tummala P; Zaslona Z; Runtsch MC; McGettrick AF; Sutton CE; Diskin C; Rooke M; Takahashi S; Sundararaj S; Casarotto MG; Dahlstrom JE; Palsson-McDermott EM; Corr SC; Mills KHG; Preston RJS; Neamati N; Xie Y; Baell JB; Board PG; O'Neill LAJ
Cell Rep; 2019 Oct; 29(1):151-161.e5. PubMed ID: 31577945
[TBL] [Abstract][Full Text] [Related]
7. Berberine Directly Targets the NEK7 Protein to Block the NEK7-NLRP3 Interaction and Exert Anti-inflammatory Activity.
Zeng Q; Deng H; Li Y; Fan T; Liu Y; Tang S; Wei W; Liu X; Guo X; Jiang J; Wang Y; Song D
J Med Chem; 2021 Jan; 64(1):768-781. PubMed ID: 33440945
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome c Negatively Regulates NLRP3 Inflammasomes.
Shi CS; Kehrl JH
PLoS One; 2016; 11(12):e0167636. PubMed ID: 28030552
[TBL] [Abstract][Full Text] [Related]
9. PKA and Epac1 Reduce Nek7 to Block the NLRP3 Inflammasome Proteins in the Retinal Vasculature.
Liu L; Jiang Y; Steinle JJ
Invest Ophthalmol Vis Sci; 2022 Jan; 63(1):14. PubMed ID: 35006270
[TBL] [Abstract][Full Text] [Related]
10. Advances in the molecular mechanisms of NLRP3 inflammasome activators and inactivators.
Liu D; Zeng X; Li X; Cui C; Hou R; Guo Z; Mehta JL; Wang X
Biochem Pharmacol; 2020 May; 175():113863. PubMed ID: 32081791
[TBL] [Abstract][Full Text] [Related]
11. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome.
Sharif H; Wang L; Wang WL; Magupalli VG; Andreeva L; Qiao Q; Hauenstein AV; Wu Z; Núñez G; Mao Y; Wu H
Nature; 2019 Jun; 570(7761):338-343. PubMed ID: 31189953
[TBL] [Abstract][Full Text] [Related]
12. Humans pIKK-up NLRP3 to skip NEK7.
Malireddi RKS; Kanneganti TD
Trends Immunol; 2022 Dec; 43(12):947-949. PubMed ID: 36404209
[TBL] [Abstract][Full Text] [Related]
13. NLRP3 inflammasome in ischemic stroke: As possible therapeutic target.
Alishahi M; Farzaneh M; Ghaedrahmati F; Nejabatdoust A; Sarkaki A; Khoshnam SE
Int J Stroke; 2019 Aug; 14(6):574-591. PubMed ID: 30940045
[TBL] [Abstract][Full Text] [Related]
14. Entrectinib inhibits NLRP3 inflammasome and inflammatory diseases by directly targeting NEK7.
Jin X; Liu D; Zhou X; Luo X; Huang Q; Huang Y
Cell Rep Med; 2023 Dec; 4(12):101310. PubMed ID: 38118409
[TBL] [Abstract][Full Text] [Related]
15. The NLRP3 Inflammasome as a Pharmacological Target.
Marchetti C
J Cardiovasc Pharmacol; 2019 Oct; 74(4):285-296. PubMed ID: 31335445
[TBL] [Abstract][Full Text] [Related]
16. NEK7: a new target for the treatment of multiple tumors and chronic inflammatory diseases.
Wang J; Chen S; Liu M; Zhang M; Jia X
Inflammopharmacology; 2022 Aug; 30(4):1179-1187. PubMed ID: 35829941
[TBL] [Abstract][Full Text] [Related]
17. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity.
He H; Jiang H; Chen Y; Ye J; Wang A; Wang C; Liu Q; Liang G; Deng X; Jiang W; Zhou R
Nat Commun; 2018 Jun; 9(1):2550. PubMed ID: 29959312
[TBL] [Abstract][Full Text] [Related]
18. Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity.
He C; Liu J; Li J; Wu H; Jiao C; Ze X; Xu S; Zhu Z; Guo W; Xu J; Yao H
J Med Chem; 2024 Jun; 67(11):9406-9430. PubMed ID: 38751194
[TBL] [Abstract][Full Text] [Related]
19. K
Groß CJ; Mishra R; Schneider KS; Médard G; Wettmarshausen J; Dittlein DC; Shi H; Gorka O; Koenig PA; Fromm S; Magnani G; Ćiković T; Hartjes L; Smollich J; Robertson AAB; Cooper MA; Schmidt-Supprian M; Schuster M; Schroder K; Broz P; Traidl-Hoffmann C; Beutler B; Kuster B; Ruland J; Schneider S; Perocchi F; Groß O
Immunity; 2016 Oct; 45(4):761-773. PubMed ID: 27692612
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting NLRP3 Inflammasome Activity in Acute Myocardial Infarction: A Review of Pharmacologic Agents and Clinical Outcomes.
Buckley LF; Libby P
J Cardiovasc Pharmacol; 2019 Oct; 74(4):297-305. PubMed ID: 31356538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
